KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Diluted Average) (2022 - 2025)

TherapeuticsMD's Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.32% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, changed 0.32%, while the annual FY2025 figure was $11.6 million, 0.32% changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $11.6 million in Q4 2025 per TXMD's latest filing, roughly flat from $11.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $11.6 million in Q2 2025 to a low of $10441.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 4 years is $9.9 million, with a median of $11.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 99.89% in 2023, then soared 110349.19% in 2024.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $9.4 million in 2022, then tumbled by 99.89% to $10441.0 in 2023, then skyrocketed by 110349.19% to $11.5 million in 2024, then grew by 0.32% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Shares Outstanding (Diluted Average) are $11.6 million (Q4 2025), $11.6 million (Q3 2025), and $11.6 million (Q2 2025).